Ustekinumab (Stelara®) for Crohn’s Disease

Assessment Status Rapid review complete
Drug Ustekinumab
Brand Stelara®
Indication For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist or have medical contraindications to such therapies
Assessment Process
Rapid review commissioned 28/11/2016
Rapid review completed 11/01/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.

 The HSE has approved reimbursement following confidential price negotiations November 2017